首页> 外文期刊>Endocrine journal >Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism
【24h】

Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism

机译:原发性醛固酮增多症患者的手术和药物治疗结果分析

获取原文
       

摘要

Patients with aldosterone-producing adenomas are treated using surgery, and patients with idiopathic hyperaldosteronism receive medical treatment using mineralocorticoid receptor antagonists (MRAs). However, the outcomes of surgical and medical treatment for primary aldosteronism (PA) remain unclear. Therefore, we compared the outcomes of surgical and medical treatment for PA and aimed to identify a specific subgroup that might benefit from medical treatment. We identified 269 patients who were treated for PA (unilateral excess 221 cases; bilateral excess 48 cases) during 2000-2015 at the Seoul National University Hospital and two other tertiary centers. The main outcomes were the amelioration of hypertension and hypokalemia. Treatment improved hypertension in the surgical treatment group (78.2%) and the medical treatment group (55.6%) (p = 0.001). At the last follow-up, hypokalemia was normalized in the surgical treatment group (97.1%) and the medical treatment group (93.7%, p = 0.046). Among patients with unilateral aldosterone excess, surgery provided advantages in resolving hypertension without worsening renal function. Among patients who were 60 years old or had impaired renal function, surgical and medical treatment provided similar amelioration of hypokalemia and hypertension. Three patients developed hyperkalemia after surgery, and no patients developed hyperkalemia after initiating medical treatment. The surgical treatment group exhibited a lower postoperative estimated glomerular filtration rate (eGFR) and higher serum potassium levels, compared to the medical treatment group. Surgical treatment provided better hypertension and hypokalemia outcomes among patients with PA, compared to medical treatment. However, MRAs may be appropriate for elderly patients with impaired renal function.
机译:患有醛固酮生成腺瘤的患者可通过手术治疗,特发性醛固酮过多症患者可使用盐皮质激素受体拮抗剂(MRA)接受治疗。然而,对于原发性醛固酮增多症(PA)的外科手术和药物治疗结果仍不清楚。因此,我们比较了PA的手术和药物治疗结果,旨在确定可能从药物治疗中受益的特定亚组。我们确定了269例在2000-2015年期间在首尔国立大学医院和其他两个专科中心接受过PA治疗的患者(单侧超过221例;双侧超过48例)。主要结果是高血压和低钾血症的减轻。手术治疗组(78.2%)和药物治疗组(55.6%)的治疗改善了高血压(p = 0.001)。在最后一次随访中,手术治疗组(97.1%)和药物治疗组(93.7%,p = 0.046)的低钾血症恢复正常。在单侧醛固酮过多的患者中,手术可在解决高血压而不恶化肾功能的情况下提供优势。在60岁以上或肾功能受损的患者中,外科手术和药物治疗可改善低血钾和高血压。三名患者在手术后出现高钾血症,没有患者在开始治疗后出现高钾血症。与药物治疗组相比,手术治疗组的术后估计肾小球滤过率(eGFR)较低,血清钾水平较高。与药物治疗相比,手术治疗在PA患者中提供了更好的高血压和低钾血症预后。但是,MRA可能适用于肾功能受损的老年患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号